aTyr Pharma Inc.
Last updated September 27, 2026
Organization details
- Legal name
- aTyr Pharma Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- ATYR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001339970
Board of directors
-
Eric Benevich · DirectorSince 2024
-
Jane A. Gross · DirectorSince 2023
-
John K. Clarke · DirectorSince 2023
-
Paul Schimmel · DirectorSince 2023
-
Sanjay Shukla · Director · President and CEOSince 2023
-
Sara Zaknoen · DirectorSince 2023
-
Svetlana Lucas · DirectorSince 2023
- Since 2023
Chief executives
Sanjay Shukla
· President and CEO
Dates unknown
Board connections
2 of this board's directors also sit on 5 other boards.
- via Timothy Coughlin
- via Timothy Coughlin
- via Svetlana Lucas
- via Timothy Coughlin
- via Timothy Coughlin
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $962,720
- 3 purchases by 1 insider
- Sold, last 12 months
- $6,293
- 3 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 27, 2026 | Paul Schimmel Director | Open-market purchase | +100,000 | $0.50 | $50,000 |
| Feb 4, 2026 | Sanjay Shukla Director, Officer (President and CEO) | Open-market sale | −3,745 | $0.98 | $3,670 |
| Feb 4, 2026 | Jill Marie Broadfoot Officer (Chief Financial Officer) | Open-market sale | −1,558 | $0.98 | $1,527 |
| Feb 4, 2026 | DENYES NANCY Officer (General Counsel) | Open-market sale | −1,118 | $0.98 | $1,096 |
| Feb 3, 2026 | Sanjay Shukla Director, Officer (President and CEO) | Option exercise | +10,375 | — | — |
| Feb 3, 2026 | Jill Marie Broadfoot Officer (Chief Financial Officer) | Option exercise | +3,750 | — | — |
| Feb 3, 2026 | DENYES NANCY Officer (General Counsel) | Option exercise | +2,687 | — | — |
| Oct 9, 2025 | Paul Schimmel Director | Open-market purchase | +317,999 | $0.94 | $298,919 |
| Oct 8, 2025 | Paul Schimmel Director | Open-market purchase | +682,001 | $0.90 | $613,801 |
| Mar 17, 2025 | Jane A. Gross Director | Open-market purchase | +3,750 | $4.00 | $15,000 |
| Feb 4, 2025 | Jill Marie Broadfoot Officer (Chief Financial Officer) | Open-market sale | −1,254 | $3.78 | $4,740 |
| Feb 4, 2025 | DENYES NANCY Officer (General Counsel) | Open-market sale | −899 | $3.78 | $3,398 |
| Feb 3, 2025 | Sanjay Shukla Director, Officer (President and CEO) | Option exercise | +10,375 | — | — |
| Feb 3, 2025 | Jill Marie Broadfoot Officer (Chief Financial Officer) | Option exercise | +3,750 | — | — |
| Feb 3, 2025 | DENYES NANCY Officer (General Counsel) | Option exercise | +2,687 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.